The UW Department of Ophthalmology and Visual Sciences is saddened to announce the passing of our friend and longtime colleague, Clare F. Hutson, MD, on January 10, 2022. He was 95 years old. A Badger …
Amy Pikalek
Meet the Newest DOVS Faculty Member: Shaoqin (Sarah) Gong
The UW Department of Ophthalmology and Visual Sciences is pleased to welcome Shaoqin (Sarah) Gong, PhD, as our newest faculty member. Gong comes to DOVS with more than 20 years of experience as a scientist, …
Roomasa Channa, MD, Selected for Competitive ARVO Leadership Program
Roomasa Channa, MD has been selected to participate in the Association for Research in Vision and Ophthalmology (ARVO) Women’s Leadership Development Program, starting in 2022. This highly-competitive program began in 2016 and is open to early- …
DOVS and UW School of Veterinary Medicine Team Up for Ocular Pathology Day
The UW Department of Ophthalmology and Visual Sciences (DOVS) and the UW School of Veterinary Medicine were proud to have successfully hosted another annual Ocular Pathology Day on September 17, 2021. The morning began virtually …
Mary Pratt, MD, Honored as Distinguished Alumni in 2020
Mary Van Horn Pratt, MD’61 (Residency ’65, Retina Fellowship ’66) was selected as the UW Ophthalmology Alumni Association’s Distinguished Alumni in October 2020. Mary was the driving force behind the campaign to update the James …
AAO Recognizes Dr. Terri Young as ‘Guest of Honor’ at 2021 Conference
Dr. Terri Young – Chair of the Department of Ophthalmology and Visual Sciences at UW-Madison – was recognized as an official ‘Guest of Honor’ at this year’s American Academy of Ophthalmology (AAO) annual conference. She …
CLN-0500
A Randomized, Parallel-Arm, Active Control, Multicenter Study Assessing the Safety and Efficacy of Dextenza for the Treatment of Ocular Pain and Inflammation Following Surgery for Pediatric Cataract
ATMOSPHERE
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD (ATMOSPHERE)
UNITY
A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Diabetic Macular Edema